Abstract:This review summarizes the results of the Danone International Probiotics Convention which examined the most recent science available on the impact of probiotics and intestinal microflora on human health. This is the second convention organized by Danone following that devoted to the 'Intelligent Intestine' which was held in Paris in June 2002 [1]. The 2003 Convention was devoted to recent scientific progress in the various field of the life sciences, enabling, not only enhanced elucidation of what happens in … Show more
“…With ageing, increased numbers of facultative anaerobes, in conjunction with a decrease in beneficial micro‐organisms such as the anaerobic lactobacilli and bifidobacteria, among other anaerobes, have been reported. Increase in Fusobacterium, Clostridium and Eubacterium , and decrease in Bacteroides and Bifidobacterium are observed (Blaut et al. 2006).…”
Section: Discussionmentioning
confidence: 99%
“…With ageing, increased numbers of facultative anaerobes, in conjunction with a decrease in beneficial micro-organisms such as the anaerobic lactobacilli and bifidobacteria, among other anaerobes, have been reported. Increase in Fusobacterium, Clostridium and Eubacterium, and decrease in Bacteroides and Bifidobacterium are observed (Blaut et al 2006). Because of the change and higher pH (7.0-7.5), proteolytic processes start to dominate in colon, which leads to increase in toxic metabolites production (ammonia, phenoles, skatoles, indoles).…”
The average β‐glucuronidase activity for children was 0.48 ± 0.04 U/mg, for adults 0.75 ± 0.27 U/mg and for elderly 1.55 ± 0.06 U/mg. For β‐glucosidase, it was 0.19 ± 0.02 U/mg for children, 0.77 ± 0.26 U/mg for adults and 1.18 ± 0.27 U/mg for elderly. In the presence of probiotics, the highest decrease in genotoxicity was observed for Lactobacillus casei 0908 (to 7.99 ± 1.32) and Lactobacillus paracasei 0919 (to 6.19 ± 1.44) for all children. In adults, lower mean genotoxicity was regarded after incubation of PhIP with L. casei 0908 (it was 5.27 ± 1.13) and L. paracasei 0919 (it was o 6.01 ± 1.00). For elderly, statistically significant decrease was maintained after incubation of PhIP with L. casei 0900 (to 6.72 ± 2.67).
“…With ageing, increased numbers of facultative anaerobes, in conjunction with a decrease in beneficial micro‐organisms such as the anaerobic lactobacilli and bifidobacteria, among other anaerobes, have been reported. Increase in Fusobacterium, Clostridium and Eubacterium , and decrease in Bacteroides and Bifidobacterium are observed (Blaut et al. 2006).…”
Section: Discussionmentioning
confidence: 99%
“…With ageing, increased numbers of facultative anaerobes, in conjunction with a decrease in beneficial micro-organisms such as the anaerobic lactobacilli and bifidobacteria, among other anaerobes, have been reported. Increase in Fusobacterium, Clostridium and Eubacterium, and decrease in Bacteroides and Bifidobacterium are observed (Blaut et al 2006). Because of the change and higher pH (7.0-7.5), proteolytic processes start to dominate in colon, which leads to increase in toxic metabolites production (ammonia, phenoles, skatoles, indoles).…”
The average β‐glucuronidase activity for children was 0.48 ± 0.04 U/mg, for adults 0.75 ± 0.27 U/mg and for elderly 1.55 ± 0.06 U/mg. For β‐glucosidase, it was 0.19 ± 0.02 U/mg for children, 0.77 ± 0.26 U/mg for adults and 1.18 ± 0.27 U/mg for elderly. In the presence of probiotics, the highest decrease in genotoxicity was observed for Lactobacillus casei 0908 (to 7.99 ± 1.32) and Lactobacillus paracasei 0919 (to 6.19 ± 1.44) for all children. In adults, lower mean genotoxicity was regarded after incubation of PhIP with L. casei 0908 (it was 5.27 ± 1.13) and L. paracasei 0919 (it was o 6.01 ± 1.00). For elderly, statistically significant decrease was maintained after incubation of PhIP with L. casei 0900 (to 6.72 ± 2.67).
“…Administration of a modified diet with proper nutritional food habits may modulate the microbial community. The use of probiotics is safe and represent beneficial provision to prevent or treat various elderly disorders (Blaut et al 2006 ). The efficiency of treatment of older adults with Bif.…”
Interspecies transmissions of viruses between animals and humans may result in unpredictable pathogenic potential and new transmissible diseases. This mechanism has recently been exemplified by the discovery of new pathogenic viruses, such as the novel severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) pandemic, Middle-East respiratory syndromecoronavirus epidemic in Saudi Arabia, and the deadly outbreak of Ebola in West Africa. The. SARS-CoV-2 causes coronavirus disease-19 (COVID-19), which is having a massive global impact in terms of economic disruption, and, above all, human health. The disease is characterized by dry cough, fever, fatigue, myalgia, and dyspnea. Other symptoms include headache, sore throat, rhinorrhea, and gastrointestinal disorders. Pneumonia appears to be the most common and severe manifestation of the infection. Currently, there is no vaccine or specific drug for COVID-19. Further, the development of new antiviral requires a considerable length of time and effort for drug design and validation. Therefore, repurposing the use of natural compounds can provide alternatives and can support therapy against COVID-19. In this review, we comprehensively discuss the prophylactic and supportive therapeutic role of probiotics for the management of COVID-19. In addition, the unique role of probiotics to modulate the gut microbe and assert gut homeostasis and production of interferon as an antiviral mechanism is described. Further, the regulatory role of probiotics on gut-lung axis and mucosal immune system for the potential antiviral mechanisms is reviewed and discussed. Key points • Gut microbiota role in antiviral diseases • Factors influencing the antiviral mechanism • Probiotics and Covid-19
“…Common problems encountered in seniors are reduced bowel function and reduced immune function. Both may be associated with changes in the composition and activity of the intestinal microbiota ( 1 , 2 ) .…”
With increasing age, a number of physiological changes take place which are reflected in immune and bowel function. These changes may relate to the commonly assumed age-related changes in intestinal microbiota; most noticeably a reduction in bifidobacteria. The current study aimed at modifying the intestinal microbiota with a potential synbiotic on selected immune and microbiota markers. Healthy elderly subjects were randomised to consume during 2 weeks either a placebo (sucrose) or a combination of lactitol and Lactobacillus acidophilus NCFM twice daily in a double-blind parallel trial. After the intervention, stool frequency was higher in the synbiotic group than in the placebo group and a significant increase in faecal L. acidophilus NCFM levels was observed in the synbiotic group, after baseline correction. In contrast to the generally held opinion, the study subjects had faecal Bifidobacterium levels that were similar to those reported in healthy young adults. These levels were, nevertheless, significantly increased by the intervention. Levels of SCFA were not changed significantly. Of the measured immune markers, PGE 2 levels were different between treatments and IgA levels changed over time. These changes were modest which may relate to the fact that the volunteers were healthy. Spermidine levels changed over time which may suggest an improved mucosal integrity and intestinal motility. The results suggest that consumption of lactitol combined with L. acidophilus NCFM twice daily may improve some markers of the intestinal microbiota composition and mucosal functions.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.